Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc Share Price

$38.92 0.1  0.2%

Last Trade - 4:05pm

Sector
Healthcare
Size
Mid Cap
Market Cap £616.9m
Enterprise Value £662.4m
Revenue £n/a
Position in Universe 2629th / 6416
Bullish
Bearish
Unlock APRE Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APRE Revenue Unlock APRE Revenue

Net Income

APRE Net Income Unlock APRE Revenue

Normalised EPS

APRE Normalised EPS Unlock APRE Revenue

PE Ratio Range

APRE PE Ratio Range Unlock APRE Revenue

Dividend Yield Range

APRE Dividend Yield Range Unlock APRE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APRE EPS Forecasts Unlock APRE Revenue
Profile Summary

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated May 3, 2019
Public Since October 3, 2019
No. of Shareholders: n/a
No. of Employees: 14
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 20,726,532
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APRE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to APRE
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.